SESSION TYPE: Pneumonia Treatment and Antibiotic Resistance
PRESENTED ON: Monday, October 22, 2012 at 04:00 PM - 05:30 PM
PURPOSE: 1. To study trends of drug-susceptilbility to Streptococcus pneumoniae in Phramonkutklao Hospital, Thailand. 2. To study risk factors and outcome of drug-resistant strain.
METHODS: data of 100 isolates Streptococcus pneumoniae from any sites (blood culture, sputum, ear, eye, and pus) until 2005 - 2011 was collected; all data such as age sex, risk factors for drug resistant strain, history of previous antimicrobial used within 3 months, and outcome of treatment were collected. Disc diffusion and E-test method were used for drugs susceptibility test in various groups of antimicrobial agents. Minimal Inhibitory Concentrations (MICs) were determined with an agar dilution method according to CLSI2011 guidelines.
RESULTS: We found Streptococcus pneumoniae - resistant strain to Penicillin, Cephalosporin, Macrolide (Erythromycin, Clarithromycin) 3,1,45 and 39% respectively. Not found drug-resistant strain in Quinolone (Levofloxacin, Moxifloxacin) and Carbapenem (Imipenem) groups. Penicillin-Resistant strain (PRSP) was found only in meningitis patients (3%). We also found higher prevalence of Macrolide resistant strain in respiratory tract infection patient (50%). Risk factors for PRSP were not associated with drug-resistant strain from our study. Macrolide-resistant strains were not affected to mortality rate.
CONCLUSIONS: Trends of drug-resistant Streptococcus pneumoniae in Phramonkutklao Hospital was increased, especially in Macrolide group. So macrolide-monotherapy should be avoided for prophylaxis or treatment in S.pneumoniae infected patient.
CLINICAL IMPLICATIONS: Macrolide monotherapy should be avoided for S.pneumoniae prophylactic used and over-the-counter medicine.
DISCLOSURE: Virissorn Wongsrichanalai: University grant monies: 28000 BTH, Grant monies (from industry related sources): GSK,MSD
No Product/Research Disclosure InformationPhramonkutklao Hospital, Bangkok, Thailand